A sermorelin allergic reaction can become an emergency. New reporting describes serious reactions after peptide injections, but it cannot tell how often they happen. Breathing trouble, throat swelling, or collapse after a shot means call 911. MedlinePlus explains these emergency signs.

What the sermorelin allergic reaction report says

As of September 30, 2026, the day this article was written, a Forbes investigation published September 25 reports reactions in five people who used peptides that stimulate growth hormone. Growth hormone is a chemical messenger involved in growth and how the body uses energy. Medicines that stimulate its release are called growth hormone secretagogues.

The lead account describes a woman who collapsed after injecting gray-market sermorelin, bought online without a prescription. Her heart rate reportedly fell to 20 beats per minute, and she briefly stopped breathing. That hospitalization happened on July 3, 2025.

The report also includes a person who had a reaction to sermorelin obtained through an online telehealth provider. A prescription does not remove the possibility of allergy.

Five interviews are a reason to take the symptoms seriously. They cannot show how common reactions are among everyone using these medicines. The publication date also does not make the older hospitalization a new September event.

What it means for someone prescribed sermorelin

The practical issue is who can review the reaction and identify what was injected. A prescribing clinician needs the allergy history, the ingredient list, and the dispensing pharmacy's records. A product name on an online storefront cannot answer those questions by itself.

Promise offers sermorelin by prescription after a licensed provider reviews your request. It is dispensed as a compounded medication, meaning a pharmacy prepares it for a prescription. The formulation offered here is not FDA-approved.

As of September 30, 2026, the day this article was written, no FDA-approved sermorelin product is currently marketed. FDA's drug database, updated September 29, lists Geref products as discontinued. Geref's pediatric treatment was approved in 1997 and withdrawn in 2009; its earlier diagnostic approval was in 1990. The FDA withdrawal record distinguishes those uses.

A licensed provider may still prescribe a compounded formulation; that decision is between the patient and the doctor.

When peptide anaphylaxis means call 911

Anaphylaxis is a severe allergic reaction that can threaten breathing or blood flow. Breathing trouble, a tight or swollen throat, tongue swelling, fainting, or collapse after an injection means call 911 immediately.

An emergency can happen without hives, the raised, itchy patches people often associate with allergy. The World Allergy Organization's 2020 guidance, available in full text, explains that skin changes can be absent.

Epinephrine is the emergency medicine used for anaphylaxis. Someone with a prescribed auto-injector, an injection device, should follow the existing emergency plan while help is called. Antihistamines, medicines that can ease itching, do not replace epinephrine for anaphylaxis.

A small sore spot after an injection is different from breathing trouble or collapse. New hives or spreading symptoms still need prompt medical assessment. Broader sermorelin side effects belong in the discussion with the prescriber; emergency symptoms need emergency care.

What the tesamorelin allergic reaction warning says

The Egrifta WR prescribing information is marked “Revised: 3/2025.” Section 5.5 states: “Hypersensitivity reactions occurred in 4% of patients treated with EGRIFTA in clinical trials.” Hypersensitivity means an allergic reaction: about 4 in 100 treated trial participants.

That figure covers reactions such as itching, redness, flushing, hives, and rash. It is not a 4% anaphylaxis rate or a sermorelin allergy rate. The label directs immediate treatment discontinuation and prompt medical attention when allergy is suspected.

Compounded tesamorelin is different from an FDA-approved product, such as Egrifta WR: the formulation offered here is not FDA-approved. The brand's indication is excess abdominal fat in adults with HIV-associated lipodystrophy, an abnormal distribution of body fat.

For someone considering prescribed tesamorelin, that warning makes the allergy history and exact ingredients relevant before treatment starts. The prescriber needs to assess the particular formulation. The wider tesamorelin side-effect profile is a separate question from whether a sudden reaction needs emergency care.

What these reports do not establish

The accounts do not establish whether a particular reaction came from the peptide itself, another ingredient, or a problem with the vial. Sorting that out needs medical assessment and, where relevant, testing of the product. Changing the name on the next vial would not answer it.

Older sermorelin studies also have limits. Vittone's 1997 trial in Metabolism included just 11 older men for six weeks and reported no significant adverse effects. A study that small cannot rule out rare serious reactions.

Vitiello's 2006 Neurobiology of Aging trial enrolled 100 older adults and compared Geref with inactive injections over six months. Its published paper describes one withdrawal for injection-site hives. It does not identify that participant's treatment group in the withdrawal description.

Neither those small studies nor five interviews provide a reliable frequency for anaphylaxis with today's compounded sermorelin formulations.

What an accountable prescription route should answer

The distinction is a provider and pharmacy that can answer specific questions, with records behind the answers. It is reasonable to ask:

  • Who is the licensed provider reviewing the allergy history and other medicines?
  • Which licensed U.S. pharmacy dispenses the prescription, and how can it be contacted?
  • What are all the ingredients, including any liquid supplied for mixing?
  • Is the starting ingredient suitable for injection, and what checks address contamination?
  • Can the pharmacy trace the lot number, which identifies the batch that supplied the vial?
  • Who receives a reaction report, and how does the patient get a callback?

These are questions to ask about the actual prescription, rather than assumptions to make from a website. Our gray-market peptide supply-chain explainer covers why the source matters.

At Promise, a licensed provider reviews every request and not everyone qualifies. That review puts a medical decision before dispensing; the allergy discussion still matters afterward.

What to watch next

The useful next evidence would connect symptoms with clinical records and identifiable products. A formal assessment could clarify the diagnosis. Testing an implicated batch could help distinguish an ingredient reaction from a quality problem. Those findings would answer more than another collection of online accounts.

FDA's MedWatch reporting guidance explains how patients and clinicians can report suspected reactions and product problems. Helpful details include the product name, timing, outcome, other medicines, and photographs of the label or packaging. Reporting follows emergency treatment; it never replaces it.

After a severe reaction, the World Allergy Organization recommends specialist assessment of the possible cause and a plan to prevent recurrence. The next decision belongs in that clinical review, with the product records available.